Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena plots its U.S. debut. Catalent is selling its oral solids development ...

The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement ...

(RTTNews) - Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, Monday said it has agreed to sell its ...

SOMERSET, N.J. - Catalent, Inc. (NYSE: NYSE:CTLT), a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, has reached a ...

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell ...

Pace Life Sciences, a division of the broader Pace organization, has acquired a laboratory in Morrisville from Catalent (NYSE: CTLT) that focuses on analytical services. Catalent is a contract ...

(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on ...

The glowing works from Siena, now at the Met, are revelatory for their emotional intensity and 24-karat beauty. By Holland Cotter Lisa Schiff acknowledges stealing millions from major collectors ...

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...